Published on March 18, 2010 at 7:16 AM
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company
focused on discovering, developing and commercializing cancer
therapeutics, today announced the completion of its initial public
offering of 9,000,000 shares of its common stock. All shares were sold
at an initial public offering price of $9.00 per share, resulting in
aggregate net proceeds to AVEO of approximately $72,580,000 after
deducting underwriting discounts and commissions and estimated offering
expenses. In addition, AVEO has granted the underwriters a 30-day option
to purchase up to an additional 1,350,000 shares to cover
over-allotments, if any.
J.P. Morgan Securities Inc. and Morgan Stanley & Co. Incorporated acted
as joint book-running managers for the offering. Leerink Swann LLC acted
as lead co-manager and Canaccord Adams Inc. acted as co-manager of the
offering.
Source AVEO
9cab4ab5-b834-4c8e-a55f-2b85446b6049|0|.0
Posted in:
Tags: Cancer